AstraZeneca To Save $60 Mil. Through PDI Sales Rep Reduction
This article was originally published in The Pink Sheet Daily
Executive Summary
No cuts will be made to the in-house sales force, AstraZeneca says. The company maintains that the decision was not in response to Exanta "not approvable" letter or the halt in Iressa promotions.
You may also be interested in...
AstraZeneca Likely To Reduce Its Contract Sales Force, PDI Says
The sales and marketing staffing firm currently contracts 800 reps to AstraZeneca.
AstraZeneca Likely To Reduce Its Contract Sales Force, PDI Says
The sales and marketing staffing firm currently contracts 800 reps to AstraZeneca.
AstraZeneca Productivity Savings Unlikely To Be Sustained Into 2006
High gross margin will be hard to maintain due to completion of one-time cost-reduction initiatives, increased marketing support and higher R&D spending.